Abstract
Ovarian cancer is one of the most lethal gynecologic malignancies in women. By the time the disease is detected, it will often have metastasized, making treatment more difficult. In patients undergoing chemotherapy, tumors initially appear responsive but most patients relapse with drug resistance. Therefore, present treatment therapies for women diagnosed with advanced ovarian cancer are poor and new approaches for treatment must be developed. Our objectives are to outline the obstacles encountered in treating ovarian cancer, the current treatment strategies and novel approaches that may improve therapeutic outcome.
Financial disclosure
M Piquette-Miller and C Allen are co-inventors on grants or patents received or pending related to the chitosan–ePC implant system.Studies involving the chitosan–ePC implant system were supported in part by grants from the Canadian Cancer Society and the Ontario Cancer Research Network.